Opinion|Videos|September 27, 2024
Established Multidisciplinary Therapies for SCLC
Panelists discuss how conventional therapies for extensive-stage and limited-stage small cell lung cancer (SCLC) have evolved, including the role of chemoradiotherapy (CRT) and its various schedules, while exploring unmet needs in extensive-stage settings and the potential for combining immunotherapies with CRT to improve treatment outcomes.
Advertisement
Episodes in this series
- What are the conventional therapies that have been used to treat extensive-stage (small cell lung cancer) SCLC and what has their data shown?
a. What are the current unmet needs in extensive-stage settings?
- What are the therapies used for limited-stage SCLC and what is the role of chemoradiotherapy (CRT), and what has the data shown?
a. What are the differences between the schedules of CRT, eg, daily/twice daily/sequential?
- Do you see opportunities in building upon CRT as a standard of care by including systemic therapies, such as immunotherapies, in combination?
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
2
Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors
3
Social Factors May Match, Outpace Genetic Risk in Disease Prediction
4
Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk
5